In recent trading session, Allogene Therapeutics Inc (NASDAQ:ALLO) saw 0.79 million shares changing hands at last check today with its beta currently measuring 1.05. Company’s recent per share price level of $2.21 trading at -$0.05 or -2.00% at last check today assigns it a market valuation of $463.37M. That most recent trading price of ALLO’s stock is at a discount of -161.54% from its 52-week high price of $5.78 and is indicating a premium of 40.27% from its 52-week low price of $1.32.

For Allogene Therapeutics Inc (ALLO), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.56. Splitting up the data highlights that, out of 6 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.32 in the current quarter.

Allogene Therapeutics Inc (NASDAQ:ALLO) trade information

Upright in the red during last session for losing -2.00%, in the last five days ALLO remained trading in the green while hitting it’s week-highest on Wednesday, 02/19/25 when the stock touched $2.21 price level, adding 41.53% to its value on the day. Allogene Therapeutics Inc’s shares saw a change of 3.76% in year-to-date performance and have moved 56.74% in past 5-day. Allogene Therapeutics Inc (NASDAQ:ALLO) showed a performance of 15.10% in past 30-days.

Wall Street analysts have assigned a consensus price target of 33.5 to the stock, which implies a rise of 93.4% to its recent value today. Analysts have been projecting 7 as a low price target for the stock while placing it at a high target of 55. It follows that stock’s current price would drop -216.74% in reaching the projected high whereas dropping to the targeted low would mean a loss of -216.74% for stock’s current value.

Allogene Therapeutics Inc (ALLO) estimates and forecasts

This year revenue growth is estimated to fall -68.42% from the last financial year’s standing.

16 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 10.5k for the same. And 12 analysts are in estimates of company making revenue of 4.17k in the next quarter. Company posted 21k and 22k of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 22.18% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 36.25% while estimates for its earnings growth in next 5 years are of 11.41%.

Allogene Therapeutics Inc (NASDAQ:ALLO)’s Major holders

FMR LLC is the top institutional holder at ALLO for having 31.26 million shares of worth $72.83 million. And as of 2024-06-30, it was holding 16.4491 of the company’s outstanding shares.

The second largest institutional holder is TPG GP A, LLC, which was holding about 18.72 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.8493 of outstanding shares, having a total worth of $43.61 million.

On the other hand, Smallcap World Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024, the former fund manager was holding 6.9 shares of worth $15.28 million or 3.29% of the total outstanding shares. The later fund manager was in possession of 4.34 shares on Sep 30, 2024, making its stake of worth around $9.61 million in the company or a holder of 2.07% of company’s stock.